MX2020005437A - Preparacion en polvo para administracion nasal. - Google Patents

Preparacion en polvo para administracion nasal.

Info

Publication number
MX2020005437A
MX2020005437A MX2020005437A MX2020005437A MX2020005437A MX 2020005437 A MX2020005437 A MX 2020005437A MX 2020005437 A MX2020005437 A MX 2020005437A MX 2020005437 A MX2020005437 A MX 2020005437A MX 2020005437 A MX2020005437 A MX 2020005437A
Authority
MX
Mexico
Prior art keywords
nasal administration
water
preparation
soluble polymer
particulate
Prior art date
Application number
MX2020005437A
Other languages
English (en)
Inventor
Koichi Minato
Tomoya Fujisawa
Kenji Shimizu
Takahisa Saito
Hiroya Yajima
Kazuhiro Sasaki
Original Assignee
Aska Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aska Pharm Co Ltd filed Critical Aska Pharm Co Ltd
Publication of MX2020005437A publication Critical patent/MX2020005437A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se prepara una preparación en polvo para administración nasal que contiene un particulado de hormonas esteroides que tiene un tamaño de partícula promedio de 50 a 300 µm como un ingrediente activo. La preparación en polvo para administración nasal puede contener además un polímero hidrosoluble (particularmente, polisacáridos hidrosolubles, tales como una celulosa que tiene un grupo hidroxialquilo). El particulado de hormonas esteroides puede ser testosterona y/o un derivado del mismo. El polímero hidrosoluble puede estar en forma particulada. La proporción del polímero hidrosoluble puede ser de aproximadamente 1 a 50 partes en peso con respecto a 1 parte en peso de las partículas de hormonas esteroides. La preparación en polvo para administración nasal puede ser una preparación en polvo para administración nasal que puede controlar una Cmáx de hormonas esteroides en no más de 15 ng/mL. Se proporciona una preparación en polvo para administración nasal que puede controlar una concentración plasmática de hormonas esteroides tal como testosterona en un intervalo específico durante un largo período de tiempo.
MX2020005437A 2017-11-27 2018-11-22 Preparacion en polvo para administracion nasal. MX2020005437A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017227133 2017-11-27
PCT/JP2018/043233 WO2019103108A1 (ja) 2017-11-27 2018-11-22 粉末経鼻投与製剤

Publications (1)

Publication Number Publication Date
MX2020005437A true MX2020005437A (es) 2020-08-27

Family

ID=66631034

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005437A MX2020005437A (es) 2017-11-27 2018-11-22 Preparacion en polvo para administracion nasal.

Country Status (10)

Country Link
US (2) US11234928B2 (es)
EP (1) EP3718550A4 (es)
JP (2) JP7321096B2 (es)
KR (1) KR102872449B1 (es)
CN (1) CN111386119A (es)
AU (1) AU2018371435B2 (es)
CA (1) CA3083757A1 (es)
MX (1) MX2020005437A (es)
TW (1) TWI797202B (es)
WO (1) WO2019103108A1 (es)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0187433B1 (en) * 1983-08-01 1990-12-27 Teijin Limited Powdery pharmaceutical composition suitable for application to mucosa of oral or nasal cavity
JPS60224616A (ja) * 1984-04-24 1985-11-09 Teijin Ltd 経鼻投与用組成物
JPS6242888A (ja) 1985-08-21 1987-02-24 カシオ計算機株式会社 太陽電池を備えたｉｃカ−ド
CN1155368C (zh) * 1996-02-27 2004-06-30 帝人株式会社 鼻腔给药的粉剂组合物
JP3197221B2 (ja) * 1996-02-27 2001-08-13 帝人株式会社 吸収性が改善された粉末状経鼻投与組成物
JP3197223B2 (ja) * 1996-02-28 2001-08-13 帝人株式会社 即効性と持続性を兼ね備えた粉末状経鼻投与用組成物
JP3197222B2 (ja) * 1996-02-28 2001-08-13 帝人株式会社 粉末状経鼻投与組成物
JP3386349B2 (ja) 1997-10-30 2003-03-17 帝人株式会社 水性懸濁医薬品組成物
JP4266399B2 (ja) * 1997-12-04 2009-05-20 帝人株式会社 粉末状吸入用医薬品組成物
AU762145C (en) 1998-08-26 2005-03-17 Teijin Limited Powdery pernasal compositions
JP2001002589A (ja) * 1999-06-18 2001-01-09 Teijin Ltd 穏やかな薬物血中濃度の上昇を可能とする経鼻投与用組成物
JP2002128704A (ja) * 2000-10-18 2002-05-09 Dotto:Kk 経鼻投与用組成物
US20040127476A1 (en) * 2002-11-14 2004-07-01 Alvin Kershman Oral testosterone delivery system with improved sustained release
ES2258694T3 (es) 2003-11-11 2006-09-01 Mattern, Udo Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales.
JP2007001926A (ja) * 2005-06-24 2007-01-11 Ltt Bio-Pharma Co Ltd 吸入・噴霧用ステロイド製剤
US20070178166A1 (en) * 2005-12-15 2007-08-02 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
CA2759109A1 (en) * 2009-04-24 2010-10-28 Iceutica Pty Ltd A solid dosage form of ciprofloxacin having small particle size and improved powder handling characteristics
US9101539B2 (en) 2009-05-15 2015-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
JP2014506936A (ja) 2011-03-03 2014-03-20 アラーガン インコーポレイテッド シリコーンベースの眼科製剤
MX2013013369A (es) * 2011-05-15 2014-10-17 Trimel Biopharma Srl Formulaciones de gel bioadhesivo de testosterona intranasal y uso del mismo para tratar hipogonadismo masculino.
WO2014144366A1 (en) * 2013-03-15 2014-09-18 Monosol Rx, Llc. Steroid hormone delivery systems and methods of preparing the same

Also Published As

Publication number Publication date
AU2018371435B2 (en) 2023-12-14
KR20200092985A (ko) 2020-08-04
AU2018371435A1 (en) 2020-07-09
CN111386119A (zh) 2020-07-07
JP7470221B2 (ja) 2024-04-17
EP3718550A4 (en) 2021-08-25
US11752102B2 (en) 2023-09-12
JP7321096B2 (ja) 2023-08-04
EP3718550A1 (en) 2020-10-07
TW201924660A (zh) 2019-07-01
WO2019103108A1 (ja) 2019-05-31
US11234928B2 (en) 2022-02-01
US20220125716A1 (en) 2022-04-28
JP2023041903A (ja) 2023-03-24
AU2018371435A2 (en) 2020-07-16
KR102872449B1 (ko) 2025-10-16
US20200360274A1 (en) 2020-11-19
JPWO2019103108A1 (ja) 2020-11-19
TWI797202B (zh) 2023-04-01
CA3083757A1 (en) 2019-05-31

Similar Documents

Publication Publication Date Title
Healy et al. Dry powders for oral inhalation free of lactose carrier particles
SA515361055B1 (ar) نواتج تكتل قابلة للاستنشاق من جسيمات حاملة مسامية وعقار بحجم الميكرون
MY175781A (en) Composition comprising at least two dry powders obtained by spray drying to increase the stability of the formulation
HRP20210025T1 (hr) Farmaceutske kompozicije koje sadrže levodop, inhibitor dopaminske dekarboksilaze i komt inhibitor i metoda administracije istih
NZ714517A (en) Delayed release cysteamine bead formulation
HRP20241719T1 (hr) Antitumorske smjese
MX368774B (es) Nueva dosificación y formulación.
EA201700182A1 (ru) Состав для повышения стабильности лекарственного препарата, содержащий по меньшей мере один сухой порошок, полученный распылительной сушкой
MX2014004279A (es) Composiciones que comprenden sulfato de salbutamol.
MX370890B (es) Composición que comprende sulfato de salbutamol.
NZ703788A (en) Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same
MX2021009757A (es) Formulacion de anestesico local de duracion prolongada.
MX2021005056A (es) Medicamentos inhalables.
HRP20240166T1 (hr) Postupak liječenja prader-willijevog sindroma
EP3505154A3 (en) Composition for improving the solubility of poorly soluble substances, use thereof and complex formulation containing thereof
MX2014014041A (es) Nueva dosificacion y formulacion.
HRP20200642T1 (hr) Čvrsti obrazac za doziranje koji sadrži mikronizirani citizin
MX2012001693A (es) Formulaciones estables no corrosivas para inhaladores presurizados de dosis medida.
EA201800266A1 (ru) Антивирусная фармацевтическая композиция
AU2014226192A8 (en) Dry pharmaceutical compositions comprising active agent nanoparticles bound to carrier particles
WO2020039264A3 (en) Chemotherapeutic pharmaceutical suspension for oral dosage
ZA202107580B (en) Formulation of (e)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4- methoxybenzylsulphone with enhanced stability and bioavailability
ZA202200335B (en) Pharmaceutical composition of temozolomide.
BR112017017385A2 (pt) formulação farmacêutica oral, e método de preparação de uma formulação farmacêutica oral
SA520420369B1 (ar) تركيبة مسحوق جاف صيدلانية للاستنشاق تشتمل على هرمون درقي